Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials

OBJECTIVE: Carfilzomib (Carf) is a second-generation proteasome inhibitor approved for patients with relapsed and/or refractory multiple myeloma (RRMM) who failed ≥ 1 prior lines of therapy. We performed a systematic review of Carf literature with meta-analysis to determine the efficacy and safety i...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Chintan, Bishnoi, Rohit, Wang, Yu, Zou, Fei, Bejjanki, Harini, Master, Samip, Moreb, Jan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955098/
https://www.ncbi.nlm.nih.gov/pubmed/29805768
http://dx.doi.org/10.18632/oncotarget.25281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955098/
https://www.ncbi.nlm.nih.gov/pubmed/29805768
http://dx.doi.org/10.18632/oncotarget.25281

Ejemplares similares